The Importance of End-to-End Quality Control Processes for RNA Biomarker Discovery
Next-generation RNA sequencing unlocks the discovery of novel candidate biomarkers for diagnostic and therapeutic applications, but reproducibility is a key challenge in biomarker discovery programs. Integrating multifaceted quality control (QC) steps can improve design decisions and enhance the confidence and reliability of results.
This webinar will demonstrate how a comprehensive QC framework using the Agilent TapeStation system supports a disease-agnostic biomarker discovery program to identify biologically relevant candidate biomarkers of complex disease. It will also highlight how this framework can be adapted for total RNA sequencing of whole blood, plasma, and serum samples.
Key learning objectives
- Learn how RNA sequencing enables the discovery of novel candidate biomarkers
- Discover how a comprehensive QC framework allows the confident identification of biologically relevant candidate biomarkers
- Understand how Agilent TapeStation systems enable reliable QC in RNA sequencing workflows
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Presenter: Cheryl Sesler, MS (Associate Director of Research, Decode Health, Inc., United States)
Presenter: Dr. Annika Dorn (Product Manager, Agilent Technologies, Germany)
